乐
乐观
乐观 · 25%AAPG
$58.30
情景价格
$15.450
+0.009 (+0.06%)收盘时
Loading chart…
- 最高
- 15.890
- 开盘
- 15.890
- 成交量加权均价
- 15.60
- 成交量
- 3.08K
- 市值
- —
- 最低
- 15.450
- 成交额
- 47.96K
- 企业价值/息税折旧摊销前利润（TTM）
- -0.48
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
AI 分析 of Ascentage Pharma Group International (AAPG)
买入Ascentage Pharma appears to be a good buy right now due to its recent Breakthrough Therapy Designation for Lisaftoclax, which could significantly enhance its market position. The current price is $15.44, with a forward P/E ratio of 10.06, indicating potential for growth. However, the stock has a year-to-date change of -41.45%, which is a risk to consider.
估值指标
Ascentage Pharma Group International（AAPG）当前预期市盈率为 10.06，5 年平均预期市盈率为 -22.29。
Alphio AI 对 AAPG 的价格情景
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。
事件时间线
资讯
9.010-20NewsfilterAscentage Pharma Receives Breakthrough Therapy Designation
6.010-14CNBCKey Wall Street Rating Changes on Wednesday
- 9.508-19Newsfilter
Ascentage Pharma Reports 29% Revenue Growth in H1 2026
5.008-02GlobenewswireAscentage Pharma Appoints New Executives to Strengthen Global Business
- 5.008-02Newsfilter
Ascentage Pharma Appoints New Executives to Strengthen Global Business
AAPG 常见问题 —— 由 Alphio AI 解答
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market. It operates in the Healthcare sector.
Ascentage Pharma appears to be a good buy right now due to its recent Breakthrough Therapy Designation for Lisaftoclax, which could significantly enhance its market position. The current price is $15.44, with a forward P/E ratio of 10.06, indicating potential for growth. However, the stock has a year-to-date change of -41.45%, which is a risk to consider.
社区
更多 ↗暂无帖子
注册或登录后参与讨论本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。